Rearming the body’s immune system to fight cancer
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Some of our partners
Latest news
Cartherics unveils new $4M lab to develop cancer immunotherapy treatments in Victoria
By Christine Filippis / October 13, 2022
MELBOURNE, Australia, 13 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has...
Read More
Cartherics granted first US patent for multiple development candidates
By Christine Filippis / October 6, 2022
Melbourne, Australia, 06 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced...
Read More
Cartherics-led Consortium Receives $5.4M Federal Funding for Cellular Immunotherapy Research into Ovarian and Gastric Cancers
By Christine Filippis / September 30, 2022
MELBOURNE, Australia, 27 September 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together...
Read More
